rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Humacyte, Inc.

HUMA · Nasdaq

Health CareBiotechnologyNot moving yet

HUMA stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 46.8% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$180K
Insider sales, 12 months
$165K
Officials’ trades on record
17
Institutions holding
155 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$12.7M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

17 disclosed lines: House 0, Senate 17, executive 0; 1 people.

WhoDidAmountTraded
Tommy Tuberville Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k3 May 2024filed 5 Aug 2026
Tommy Tuberville Senate: U.S. Senate eFDSenatorsold part ofjoint$15k–$50k3 May 2024filed 5 Aug 2026
Tommy Tuberville Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k3 May 2024filed 14 Jun 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorsold part ofjoint$15k–$50k3 May 2024filed 14 Jun 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorsold part ofjoint$50k–$100k30 Apr 2024filed 15 May 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$1k–$15k21 Mar 2024filed 5 Aug 2026
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$1k–$15k21 Mar 2024filed 5 Aug 2026
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$15k–$50k21 Mar 2024filed 5 Aug 2026
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$1k–$15k21 Mar 2024filed 15 Apr 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$1k–$15k21 Mar 2024filed 15 Apr 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$15k–$50k21 Mar 2024filed 15 Apr 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$15k–$50k12 Feb 2024filed 15 Mar 2024

Insiders

Buy orders, 12 months5
Sale orders, 12 months2
Buyers · sellers3 · 2
WhoDidSharesTraded
Keith Anthony JonesDirectorbought10,000at $0.56214 Sep 2026filed 15 Sep 2026
Keith Anthony JonesDirectorbought10,000at $0.69320 Aug 2026filed 21 Aug 2026
Keith Anthony JonesDirectorbought30,000at $0.59417 Aug 2026filed 19 Aug 2026
Kathleen SebeliusDirectorbought56,818at $0.8819 May 2026filed 20 May 2026
Michael T. ConstantinoDirectorbought11,000at $0.894518 May 2026filed 20 May 2026
Dale A. SanderCFO and Chief Corp. Dev. Offsold45,887at $0.896718 May 2026filed 20 May 2026
Shamik J. ParikhChief Medical Officersold45,887at $0.896718 May 2026filed 20 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders155+6 on the quarter
New · exited39 · 34
Reported value$55.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202610,107,679$7.9M+2,949,517+41.2%
ANTIPODES PARTNERS Ltdadded · filed 6 Aug 202610,103,647$7.9M+4,379,897+76.5%
Alyeska Investment Group, L.P.new · filed 14 Aug 20266,022,925$4.7M+6,022,925
Davidson Kempner Capital Management LPnew · filed 14 Aug 20265,000,000$3.9M+5,000,000
BlackRock, Inc.reduced · filed 7 Aug 20264,839,929$3.8M-7,477,026−60.7%
GREAT POINT PARTNERS LLCunchanged · filed 14 Aug 20263,750,000$2.9M00.0%
UBS Group AGadded · filed 13 Aug 20262,843,493$2.2M+61,423+2.2%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20262,597,134$2.0M+672,443+34.9%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 20262,185,225$1.7M-1,472,883−40.3%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20261,909,049$1.5M+1,800,895+1665.1%
31 Mar 2023 – 30 Jun 2026
56104151Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

D. Scott Coward Company insiderDirector · last 6 Oct 20260 · 0
Paul Brian Kuznik Company insiderDirector · last 6 Oct 20260 · 0
Keith Anthony Jones Company insiderDirector · last 14 Sep 20263 · 0
Brady W. Dougan Company insiderDirector · last 11 Jun 20268 · 31
Charles Bruce Green Company insiderDirector · last 11 Jun 20261 · 0
Diane Seimetz Company insiderDirector · last 11 Jun 20260 · 0
Emery N. Brown Company insiderDirector · last 11 Jun 20260 · 0
John Philip Bamforth Company insiderDirector · last 11 Jun 20260 · 0
Kathleen Sebelius Company insiderDirector · last 11 Jun 20262 · 1
Laura E. Niklason Company insiderPresident, CEO and Director · last 11 Jun 20268 · 31
Max N. Wallace Company insiderDirector · last 11 Jun 20261 · 0
Michael T. Constantino Company insiderDirector · last 11 Jun 20267 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-110%
Debt to equityFY 2025 · to 31 Dec 202511.40×
Share count trendFY 2025 · to 24 Mar 202615.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$50.5M
Free cash flowFY 2025 · to 31 Dec 2025−$105.9M

Analyst forecasts

No analyst forecasts yet.